arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Nuvectis Pharma, Inc.

NVCT
$21.14 ▼ -1.88 (-8.17%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
23 Visible periods
17 Metrics
Peer-ranked Benchmarks
Price Chart
16
Health
Poor
Bearish
auto_awesome

Analytical Summary

Nuvectis Pharma, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $496.3M
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC -62.6% ↘
FCF / Share $-0.19 ↗
Trailing P/E —
Price / Book 62.1x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

23-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-6.05M
↓ -13.5% —
FCF / Share Free cash flow per share
$-0.19
↑ +30.6% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
5
Cash Quality ↓
44

Dividend History

Dividend / share · sourced from SEC filings
$0.00 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 6 years · 23 quarters